Open AccessNew Drug Review: Lurasidone (Latuda®) - The new antipsychotic on the block
Author(s) -
Kelly N. Gable
Publication year - 2011
Publication title -
mental health clinician
Language(s) - English
Resource type - Journals
ISSN - 2168-9709
DOI - 10.9740/mhc.n89387
Subject(s) - lurasidone , medicine , food and drug administration , antipsychotic drug , drug , adverse effect , pharmacology , clinical trial , antipsychotic , intensive care medicine , psychiatry , schizophrenia (object oriented programming)
Lurasidone was approved by the Food and Drug Administration (FDA) in 2011. This article reviews clinically significant aspects of this new drug including: the FDA-approved indications, mechanism of action, administration, drug interactions, adverse effects, clinical trial evidence, innovative properties and place in therapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom